2022
AML-055 Outcomes Based on Sequential Use of Venetoclax Based Therapy and Targeted Therapy in Acute Myeloid Leukemia (AML)
Stahl M, Shallis R, Derkach A, Goldberg A, Stein A, Stein E, Marcucci G, Zeidan A, Shimony S, DeAngelo D, Stone R, Aldoss I, Ball B, Bewersdorf J. AML-055 Outcomes Based on Sequential Use of Venetoclax Based Therapy and Targeted Therapy in Acute Myeloid Leukemia (AML). Clinical Lymphoma Myeloma & Leukemia 2022, 22: s209-s210. DOI: 10.1016/s2152-2650(22)01214-9.Peer-Reviewed Original ResearchOverall response rateAcute myeloid leukemiaMorphologic leukemia-free stateOverall survivalComplete responseIDH2 inhibitorsMedian OSPartial remissionTargeted therapyEffective salvage therapyIncomplete count recoveryMedian overall survivalShorter median OSRetrospective cohort studyShorter overall survivalAcademic cancer centerFLT3-ITD mutationAlternative therapeutic strategiesSalvage therapyCohort studyCount recoveryInhibitor therapyTargeted agentsClinical efficacyCancer Center
2021
Disparity in utilization of multiagent therapy for acute promyelocytic leukemia (APL): A large National Cancer Database (NCDB) analysis.
Dhakal P, Lyden E, Gundabolu K, Zeidan A, Loh K, Fisher A, Bhatt V. Disparity in utilization of multiagent therapy for acute promyelocytic leukemia (APL): A large National Cancer Database (NCDB) analysis. Journal Of Clinical Oncology 2021, 39: 6587-6587. DOI: 10.1200/jco.2021.39.15_suppl.6587.Peer-Reviewed Original ResearchSingle-agent therapyAcute promyelocytic leukemiaCommunity cancer centerMultiagent therapyAgent therapyCancer CenterReal-world practiceUninsured patientsClinical trialsComprehensive community cancer centerNational Cancer Database AnalysisMultiple logistic regression analysisFindings highlight disparitiesLower comorbidity indexThird of patientsAcademic cancer centerAppropriateness of treatmentHealth system factorsAcute myeloid leukemiaLogistic regression analysisUnknown therapyComorbidity indexGreater comorbidityMultiagent chemotherapyOverall survival
2018
Does Provider Experience Treating Patients (pts) with Myelodysplastic Syndromes (MDS) Explain Duration of Hypomethylating Agent (HMA) Therapy and Overall Survival (OS)? A Large Population-Based Analysis
Zeidan A, Hu X, Zhu W, Stahl M, Giri S, Huntington S, Wang R, Podoltsev N, Gore S, Ma X, Davidoff A. Does Provider Experience Treating Patients (pts) with Myelodysplastic Syndromes (MDS) Explain Duration of Hypomethylating Agent (HMA) Therapy and Overall Survival (OS)? A Large Population-Based Analysis. Blood 2018, 132: 370. DOI: 10.1182/blood-2018-99-111052.Peer-Reviewed Original ResearchHMA cyclesOverall survivalHMA initiationHMA therapyMyelodysplastic syndromeProvider typeCancer CenterMD volumeMultivariate Cox proportional hazardsKaplan-Meier log-rank testAZA-001 trialMedian overall survivalTwo-sided statistical testsLog-rank testReal-world survivalCox proportional hazardsLogistic regression analysisWilcoxon rank sum testChi-square testCommunity-based practiceRank sum testEligible ptsLookback periodEarly discontinuationAgent therapy
2015
Myelodysplastic syndromes: from conductiong clinical trials of novel therapies to evaluating real-life effectiveness of exisiting therapies
Zeidan A. Myelodysplastic syndromes: from conductiong clinical trials of novel therapies to evaluating real-life effectiveness of exisiting therapies. International Journal Of Hematologic Oncology 2015, 4: 215-217. DOI: 10.2217/ijh.15.25.Peer-Reviewed Original ResearchMyelodysplastic syndromeHematologic malignanciesNovel therapiesYale Cancer CenterReal-life effectivenessMyeloid hematologic malignanciesHematology/oncology fellowshipRochester General HospitalInternal medicine residencyCancer CenterClinical trialsGeneral HospitalClinical investigationFaculty of MedicineOncology fellowshipsMalignancyTherapyClinical interestTranslational researchMedicine residencyOutcomes researchMBBS degreeMedicineJohns Hopkins UniversityResearch Fellowship